Product
Enavogliflozin
4 clinical trials
6 indications
Indication
Diabetes MellitusIndication
Type 2Indication
Aortic Valve StenosisIndication
Tricuspid RegurgitationIndication
Type 2 DiabetesClinical trial
A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Envlo Tablet in Patients With Type II Diabetes MellitusStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Open-Label, Parallel Group Trial to Evaluate the Effect of ENAVOgliflozin Compared With Standard-of-Care on Reduction of Adverse Clinical Events and Cardiac Reverse Remodeling in Patients Who Underwent Transcatheter Aortic Valve ImplantationStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Enavogliflozin on Outcomes in Patients With Functional Tricuspid Regurgitation and Heart Failure With Preserved Left Ventricular Ejection FractionStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin With/Without Dipeptidyl Peptidase-4 Inhibitors in Type 2 DiabetesStatus: Recruiting, Estimated PCD: 2026-06-01